Compare Danaher Corporation (DHR) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Victoria's Secret & Co — how do they compare? Danaher Corporation trades at $200.93 (market cap $140.88B), while Victoria's Secret & Co trades at $84.19 (market cap $6.51B). The key difference: Danaher Corporation is far larger — about 21.6× Victoria's Secret & Co's market cap, and Danaher Corporation pays a 0.8% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| DHR | VSXY | |
|---|---|---|
Market Cap | $140.88B | $6.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $88.50 |
52-Week Low | $161.91 | $17.70 |
Enterprise Value | $153.66B | $9.16B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Victoria's Secret (VSXY) trades at $78.98, up 0.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and international growth momentum, particularly a 44.9% surge in Q1 2026 international sales, highlight operational improvements. The stock shows recovering profitability with a net income margin of 3.12% and robust ROE of 29.41%, though valuation metrics like a P/E of 31.47 suggest premium pricing relative to earnings.
The outlook remains positive with a consensus price target of $88.56 implying 12% upside, driven by innovation and global expansion. Risks include competitive pressures and reliance on margin recovery. Institutional sentiment is favorable with no sell ratings, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
